Tianjin Ninehealth Medical Technology Co., Ltd.
2025 Annual Report of Independent Directors
As an independent director of Tianjin Ninehealth Medical Technology Co., Ltd. (hereinafter referred to as the "Company"), I have strictly adhered to the "Company Law," "Corporate Governance Guidelines for Listed Companies," "Stock Listing Rules of the Shenzhen Stock Exchange," and other relevant laws, regulations, and the "Articles of Association" and "Independent Director System" and other rules and requirements. My fundamental purpose has been to safeguard the legitimate interests of all shareholders, especially small and medium shareholders, by diligently and conscientiously exercising my rights as an independent director. This year, I carefully reviewed various meeting proposals and materials of the Company, and based on my professional background, provided professional opinions and constructive suggestions for the Company's operational management, business development, and strategic planning. I have fully leveraged my professional supervision and decision-making support role to contribute to the Company's standardized, stable, and healthy development. The following is my report on fulfilling my duties as an independent director in 2025:
I. Basic Information of Independent Directors
Sun Weijun, male, born in July 1976, Chinese national, with no permanent residency abroad. He holds a Ph.D. in Management Science and Engineering from Tianjin University and holds the title of Senior Engineer. He is currently the Chairman of Tianjin Xinhua Tongli Management Consulting Co., Ltd., the Director and General Manager of Tianjin Haitang Zhi Ben Entrepreneurship Technology Co., Ltd., and a Director of Tianjin Senluo Technology Co., Ltd. He also serves as the Vice Chairman and Secretary-General of the Tianjin Binhai New Area Entrepreneurs Club, the Legal Representative, Vice Chairman, and Secretary-General of the Tianjin Enterprise Technology Innovation Promotion Association, the Vice Dean of the Tianjin University Xuanhuai College, and concurrently serves as an independent director of Tianjin Rongtianyu.
During the reporting period, my position met the independence requirements stipulated in Article 6 of the "Administrative Measures for Independent Directors of Listed Companies," and there were no circumstances affecting my independence.
II. Overview of Performance in the Reporting Year
- Attendance at Board Meetings, Shareholder (General) Meetings, and Voting
In 2025, the Company held a total of 13 board meetings and 5 general meetings. I strictly adhered to the requirements of relevant laws, regulations, and the Company's internal rules, and consistently performed my duties as an independent director with diligence and responsibility. During the reporting period, I attended all board meetings in person and did not have any absences or authorize others to attend on my behalf. The specific attendance situation is as follows:
| Board Meetings | Shareholder (General) Meetings | |
|---|---|---|
| Should Attend | 13 | 5 |
| Attended in Person | 13 | 5 |
| Voted Against | 0 | |
| Consecutive Two Times Not Attended in Person | N/A | No |
- Key Areas of Focus and Performance
On March 25, 2025, I participated in the first specialized meeting of independent directors in 2025. The attendees, in conjunction with relevant rules, determined that the Company met the conditions for share repurchase. We discussed key aspects such as the purpose and use of this repurchase, the methods and price range for repurchasing shares, the types, number, and proportion of shares to be repurchased relative to the Company's total share capital, the total amount of funds intended for repurchase, the sources of funds, and the implementation period. The proposal on the Company's share repurchase plan was deliberated and approved.